ReviewHealthcare (Basel, Switzerland)2025
Redefining Obesity: A Narrative Review of Diagnostic Evolution, Therapeutic Strategies and Psychosocial Determinants.
Review in Healthcare (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Community-Based Non-Pharmacological Intervention for Metabolic Syndrome in Chile: A Comparative Reanalysis of an Integrated Exercise and Health Education Program.International journal of environmental research and public health · 2026Trial
- Trends in Diagnosing Obesity: The CALOR Study.Obesity (Silver Spring, Md.) · 2026Article
- Review
- Ibero-American position statement on therapeutic recommendations for the preventive management of cardiovascular complications in latin-American patients with type 2 diabetes mellitus: consensus of the prevention council of the inter-American society of cardiology (SIAC-PREVENT).Diabetology & metabolic syndrome · 2026Review
- Supporting and Non-Stigmatizing Communication in the Process of Weight Change: The Role of Motivational Interviewing.Nutrients · 2026Review
- Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes.Metabolism open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is increasingly recognized as a chronic, relapsing, and multifactorial disease requiring individualized care. This narrative review synthesizes recent developments in the definition, diagnosis, and treatment of obesity, highlighting key shifts in diagnostic frameworks (e.g., ICD-11), advances in pharmacotherapy, and the psychosocial dimensions shaping care engagement. Limitations of BMI, the impact of stigma, and structural inequities are discussed as barriers to effective management. By integrating clinical, psychological, and societal perspectives, this review advocates for a multidimensional, stigma-informed, and equity-oriented approach to obesity care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.